Age-Dependent Effects of GLP-1 Receptor Agonists on Clinical Outcomes in Inflammatory Bowel Disease: A Propensity-Matched Real-World Study (ACG 2026) - Aug 29, 2026 - Abstract #P1148; Pres time: Oct 11, 2026; 03:30 PM - 07:00 PM; Location: Exhibit Halls A - D (Level 3); "Within each, GLP-1 RA users were propensity score matched 1:1 to non-users on gender; race/ethnicity (Hispanic, White, African-American, Asian, other); type 2 diabetes; Crohnâs disease; ulcerative colitis; hyperlipidemia; hypertension; ischemic heart disease; CKD; MASLD; obesity; insulin; SGLT2 inhibitors; prior hospitalization; and baseline IBD therapy including aminosalicylates (mesalamine, sulfasalazine), thiopurines/immunomodulators (azathioprine, mercaptopurine, methotrexate), anti-TNF agents (infliximab, adalimumab, certolizumab pegol, golimumab), vedolizumab, IL-12/23 and IL-23 inhibitors (ustekinumab, risankizumab), and JAK inhibitors (tofacitinib, upadacitinib). Primary cohorts (vs non-users): 1,958 (18â45), 5,412 (45â65), 2,928 ( >65). GLP-1 RA use was associated with lower hospitalization, ED visits, and IV corticosteroid use across all cohorts (Table 1, Figure 1). The 45â65 cohort had the most comprehensive..."
Clinical • Clinical data • Real-world • Real-world evidence • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Crohn's disease • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Hypertension • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Obesity • Pancreatitis • Renal Disease • Type 2 Diabetes Mellitus • Ulcerative Colitis • IL12A • IL23A
|
|
Kavin Parmar MD 1; Mason Faykus 2; Krishan S. Patel MD 3; Vaidehi Kothari MD 1; Hem Shah MD 4; Krishna Vamsy Polepalli MD 1; Umesh Bhagat MD 5; Archana Kharel MD 6; Prajith Raj Ramesh MBBS 7; Prabhat Kumar MD 2; Raseen Tariq MD MS 2
|